Oct 12, 2024 | By Jason Kwon | 22 |
These startups develop new technologies to improve vision and cure cataract, glaucoma, myopia, hyperopia, astigmatism, presbyopia, blindness.
1
Lumata Health
Country: USA | Funding: $15M
Lumata Health is a practice management platform for ophthalmology
2
XP Health
Country: USA | Funding: $54M
XP Health is an artificial intelligence-powered vision benefits platform for employees.
3
Spark Therapeutics
Country: USA | Funding: $763.8M
Spark is a leader in the field of gene therapy, seeking to transform the lives of patients by developing potential one-time, life-altering treatments for debilitating genetic diseases. We initially are applying our integrated platform to treat rare diseases where no, or only palliative, therapies exist.
4
Pliant Therapeutics
Country: USA | Funding: $694.9M
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
5
Emendo Biotherapeutics
Country: USA | Funding: $317.8M
Emendo Biotherapeutics develops gene editing platform to expand the list of diseases amenable to treatment with gene editing, resulting in a pipeline of hematology and ophthalmology programs.
6
Zenas BioPharma
Country: USA | Funding: $318M
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients (including with Thyroid Eye Disease ).
7
Beacon Therapeutics
Country: UK | Funding: $290.1M
Beacon Therapeutics is an ophthalmic gene therapy company to treat blinding retinal illnesses and restore and enhance eyesight.
8
Gyroscope Therapeutics
Country: UK | Funding: $269.5M
Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system
9
GenSight Biologics
Country: France | Funding: $263.9M
We are a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.
10
Avedro
Country: USA | Funding: $218.5M
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking.
11
Digital Diagnostics
Country: USA | Funding: $173.4M
IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. The company’s first product, IDx-DR, is an FDA-cleared AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy. IDx is developing additional AI-based diagnostic algorithms for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk.
12
Second Sight
Country: USA | Funding: $153.9M
Through dedication and innovation, Second Sight's mission is to develop, manufacture and market implantable visual prosthetics to enable blind individuals to achieve greater independence. The Argus II Retinal Prosthesis System (“Argus II”) is also known as the bionic eye or the retinal implant. It is intended to provide electrical stimulation of the retina to induce visual perception in blind individuals with severe to profound Retinitis Pigmentosa.
13
Gemini Therapeutics
Country: USA | Funding: $139.5M
Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies.
14
OrCam
Country: Israel | Funding: $130M
OrCam’s mission is to harness the power of artificial vision by incorporating pioneering technology into a wearable platform which improves the lives of individuals who are blind, visually impaired, and have reading difficulties. OrCam has created a technologically advanced device unique in its ability to provide visual aid through a discreet wearable platform and simple easy-to-use interface which serves to enhance the daily lives of people with vision loss.
15
SparingVision
Country: France | Funding: $127.6M
SparingVision is a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa.
16
Orasis Pharmaceuticals
Country: Israel | Funding: $126M
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia as an alternative to reading glasses.
17
Aurion Biotech
Country: USA | Funding: $120M
Aurion Biotechnologies is on mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases.
18
MeiraGTx
Country: USA | Funding: $112.7M
Meira Gene Therapy is argeting inherited retinal diseases with therapies designed to halt vision loss.
19
Atsena Therapeutics
Country: USA | Funding: $87.6M
Atsena Therapeutics develops blindness gene therapy
20
Coave Therapeutics
Country: France | Funding: €79.1M
Coave Therapeutics develops retinal gene therapy
Load More Startups
Editor: Jason Kwon
Jason Kwon is a senior editor for MedicalStartups. He has previously covered the pharmaceutical and medical research industries for FDAnews and worked as a head of marketing for medical startup Sonic Therapeutics. Before that, he co-founded a startup consulting business for emerging entrepreneurial hubs in Asia. Jason graduated from St. Bonaventure University’s journalism school. In his free time, Jason enjoys yoga, watching movie trailers, traveling to places where he can't get cell service. You can contact Jason at jaskwon(at)medicalstartups(dot)com
